Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study

20260 citationsJournal Articlehybrid Open Access

Authors

Jun Hwa Hong · Eulji University

Sung Hoon Yu · Hanyang University Guri Hospital

Baek Ki-Hyun · The Catholic University of Korea Yeouido St. Mary's Hospital

JaeMyung Yu · Hallym University Kangnam Sacred Heart Hospital

Seung Jin Lee · Soonchunhyang University

Hyung-Wook Kim · The Catholic University of Korea St. Vincent's Hospital

K. Park

Abstract

Evogliptin reduces blood glucose levels and is well-tolerated when used as an add-on, as a switch from other dipeptidyl peptidase 4 inhibitors, or as part of an initial combination therapy in patients with type 2 diabetes mellitus.

Topics & Keywords

Diabetes Treatment and Management Heart Failure Treatment and Management Cancer Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.70601

Field-Weighted Citation Impact: 0.00